(0.31%) 5 115.71 points
(0.31%) 38 357 points
(0.34%) 15 982 points
(-0.88%) $83.11
(5.77%) $2.03
(0.39%) $2 356.30
(0.47%) $27.67
(4.05%) $959.40
(-0.23%) $0.933
(-0.38%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
@ $17.66
発行日: 15 2月 2024 @ 04:01
リターン: -10.76%
前回のシグナル: 2月 14 - 05:45
前回のシグナル:
リターン: 3.03 %
Live Chart Being Loaded With Signals
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States...
Stats | |
---|---|
本日の出来高 | 241 542 |
平均出来高 | 1.26M |
時価総額 | 2.25B |
EPS | $0 ( 2024-02-26 ) |
次の収益日 | ( $-0.670 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.87 |
ATR14 | $0.0120 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Sato Vicki L | Sell | 1 666 | Common Stock |
2024-04-01 | Krognes Steve E. | Sell | 92 500 | Common Stock |
2024-03-29 | Watts Ryan J. | Sell | 40 000 | Common Stock |
2024-03-15 | Sato Vicki L | Sell | 1 666 | Common Stock |
2024-02-15 | Sato Vicki L | Sell | 1 666 | Common Stock |
INSIDER POWER |
---|
33.10 |
Last 100 transactions |
Buy: 1 164 016 | Sell: 631 404 |
ボリューム 相関
Denali Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
MBIN | -0.912 |
SCR | -0.902 |
KTCC | -0.901 |
MPWR | -0.897 |
ZIONP | -0.891 |
HUGE | -0.889 |
WIRE | -0.889 |
ITI | -0.888 |
PAE | -0.888 |
ICPT | -0.888 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Denali Therapeutics Inc 相関 - 通貨/商品
Denali Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $330.53M |
総利益: | $313.81M (94.94 %) |
EPS: | $-1.060 |
FY | 2023 |
収益: | $330.53M |
総利益: | $313.81M (94.94 %) |
EPS: | $-1.060 |
FY | 2022 |
収益: | $108.46M |
総利益: | $101.43M (93.52 %) |
EPS: | $-2.60 |
FY | 2021 |
収益: | $48.66M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.40 |
Financial Reports:
No articles found.
Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。